These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 8391072

  • 1. Clinical pharmacology of angiotensin and bradykinin in human forearm vasculature.
    Ritter JM, Cockcroft JR, Sciberras DG, Goldberg MR.
    J Hypertens Suppl; 1993 Apr; 11(3):S59-61. PubMed ID: 8391072
    [Abstract] [Full Text] [Related]

  • 2. Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm.
    Cockcroft JR, Sciberras DG, Goldberg MR, Ritter JM.
    J Cardiovasc Pharmacol; 1993 Oct; 22(4):579-84. PubMed ID: 7505360
    [Abstract] [Full Text] [Related]

  • 3. The advantages of angiotensin II antagonism.
    Burnier M, Waeber B, Brunner HR.
    J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
    [Abstract] [Full Text] [Related]

  • 4. Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure.
    Cruden NL, Witherow FN, Webb DJ, Fox KA, Newby DE.
    Arterioscler Thromb Vasc Biol; 2004 Jun; 24(6):1043-8. PubMed ID: 15105283
    [Abstract] [Full Text] [Related]

  • 5. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
    Goldberg MR, de Mey C, Wroblewski JM, Li Q, Schroeter V, Belz GG.
    Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
    [Abstract] [Full Text] [Related]

  • 6. Angiotensin II blockade compared with other pharmacological methods of inhibiting the renin-angiotensin system.
    Brunner HR, Nussberger J, Waeber B.
    J Hypertens Suppl; 1993 Apr; 11(3):S53-8. PubMed ID: 8315521
    [Abstract] [Full Text] [Related]

  • 7. Blockade of the renin-angiotensin system in heart failure in conscious dogs.
    Murakami M, Suzuki H, Naitoh M, Matsumoto A, Kageyama Y, Tsujimoto G, Saruta T.
    J Hypertens; 1995 Dec; 13(12 Pt 1):1405-12. PubMed ID: 8866902
    [Abstract] [Full Text] [Related]

  • 8. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M, Brunner HR.
    Exp Nephrol; 1996 Dec; 4 Suppl 1():41-6. PubMed ID: 9001896
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin II-receptor (AT1) blockade in the human forearm.
    Ritter JM, Cockcroft JR.
    Blood Press Suppl; 1996 Dec; 2():67-70. PubMed ID: 8913543
    [Abstract] [Full Text] [Related]

  • 10. Juxtaglomerular cell hypertrophy and hyperplasia induced in rhesus monkeys by angiotensin II receptor antagonists.
    Owen RA, Molon-Noblot S, Hubert MF, Siegl PK, Eydelloth RS, Keenan KP.
    Lab Invest; 1994 Oct; 71(4):543-51. PubMed ID: 7967510
    [Abstract] [Full Text] [Related]

  • 11. Angiotensin-converting enzyme inhibition and angiotensin AT1-receptor antagonism equally improve endothelial vasodilator function in L-NAME-induced hypertensive rats.
    De Gennaro Colonna V, Rigamonti A, Fioretti S, Bonomo S, Manfredi B, Ferrario P, Bianchi M, Berti F, Muller EE, Rossoni G.
    Eur J Pharmacol; 2005 Jun 15; 516(3):253-9. PubMed ID: 15963975
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II antagonists: a new class of antihypertensive agent.
    Waeber B, Brunner HR.
    Br J Clin Pract; 1996 Jun 15; 50(5):265-8. PubMed ID: 8794603
    [Abstract] [Full Text] [Related]

  • 13. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B.
    J Hum Hypertens; 1995 Nov 15; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [Abstract] [Full Text] [Related]

  • 14. [Hormonal contribution to short-term variability of blood pressure in a renovascular hypertension model].
    Ponchon P, Elghozi JL.
    Arch Mal Coeur Vaiss; 1995 Aug 15; 88(8):1203-7. PubMed ID: 8572874
    [Abstract] [Full Text] [Related]

  • 15. Localization of components of the renin-angiotensin system and site of action of inhibitors.
    Chai SY, Zhuo J, Mendelsohn FA.
    Arzneimittelforschung; 1993 Feb 15; 43(2A):214-21. PubMed ID: 8498967
    [Abstract] [Full Text] [Related]

  • 16. The future role of losartan.
    Hansson L.
    J Hum Hypertens; 1995 Nov 15; 9 Suppl 5():S55-8. PubMed ID: 8583483
    [Abstract] [Full Text] [Related]

  • 17. Clinical experience with angiotensin II receptor antagonists.
    Lee RJ, Brunner HR.
    J Hum Hypertens; 1993 Aug 15; 7 Suppl 2():S33-6. PubMed ID: 8230087
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Effects of the angiotensin type I receptor antagonist, losartan, on systemic and regional vascular responses to lower body negative pressure in healthy volunteers.
    Duranteau J, Pussard E, Berdeaux A, Giudicelli JF.
    Br J Clin Pharmacol; 1995 Nov 15; 40(5):431-8. PubMed ID: 8703646
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.